StockDuty ← Dashboard Sep 28, 2026 08:57 PM ET
SignalJapan

HALF OF NEW US-APPROVED DRUGS REMAIN UNAVAILABLE TO JAPANESE PATIENTS - NIKKEI

Half of new US-approved drugs unavailable to Japanese patients, highlighting Japan drug lag.

Half of new US-approved drugs unavailable to Japanese patients, highlighting Japan drug lag.
Half of new US-approved drugs unavailable to Japanese patients, highlighting Japan drug lag. — impact context not separately stored; see What changed.
Sources